178310-89-9

Downstream Products

• 178312-35-1 (S)-1-(2-Cyclopropyl-ethyl)-5-(3,4-dichloro-phenyl)-5-[1,3]dioxolan-2-ylmethyl-piperidin-2-one 
• 191997-27-0 5(S)-1-Cyclopropylmethyl-5-(3,4-dichlorophenyl)-5-(1,3-dioxolan-2-ylmethyl)-2-piperidone 
• 178312-39-5 5(S)-5-(3,4-Dichlorophenyl)-5-formylmethyl-2(1H)-piperidone 
• 193755-86-1 3(S)-3-(3,4-Dichlorophenyl)-3-(1,3-dioxolan-2-ylmethyl)piperidine 
• 178312-08-8 [(S)-1-Cyclohexylmethyl-3-(3,4-dichloro-phenyl)-6-oxo-piperidin-3-yl]-acetaldehyde 
• 178312-07-7 [(S)-1-Cyclopropylmethyl-3-(3,4-dichloro-phenyl)-6-oxo-piperidin-3-yl]-acetaldehyde 
• 178312-09-9 [(S)-3-(3,4-Dichloro-phenyl)-1-(4,4-difluoro-cyclohexylmethyl)-6-oxo-piperidin-3-yl]-acetaldehyde 
• 178312-40-8 [(S)-1-(2-Cyclopropyl-ethyl)-3-(3,4-dichloro-phenyl)-6-oxo-piperidin-3-yl]-acetaldehyde 

Relevant academic research and scientific papers

3-Azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists

The present invention provides compounds of formula (I) and the pharmaceutically acceptable salts thereof. Such compounds and salts are tachykinin antagonists.

Piperidone tachykinin antagonists

The present invention provides compounds of formula (I) and the pharmaceutically acceptable acid addition salts thereof, wherein X is a direct link or C1-C4alkylene; and R is C3-C7cycloalkyl optionally substituted by 1 or 2 substituents each independently selected from fluoro and C3-C7cycloalkyl: with the proviso that X is not methylene when R is cyclopropyl, together with processes for the preparation of, intermediates used in the preparation of, compositions containing and uses of, such compounds. These compounds are useful as tachykinin antagonists.

(Azetidin-1-ylalkyl) lactams as tachykinin antagonists

The present invention provides compounds of formula (I) and the pharmaceutically acceptable salts thereof, wherein R is C3 -C7 cycloalkyl, aryl or C1 -C6 alkyl, said C1 -C6 alkyl, said C1 -C6 alkyl being optionally substituted by fluoro, COOH, --COO(C1 -C4 alkyl), C3 -C7 cycloalkyl, adamantyl, aryl or het1, and said C3 -C7 cycloalkyl being optionally substituted by 1 or 2 substituents each independently selected from C1 -C4 alkyl, C3 -C7 cycloalkyl, C1 -C4 alkoxy, hydroxy, fluoro, fluoro (C1 -C4) alkyl and fluoro (C1 -C4) Alkoxy; R1 is phenyl, naphthyl, thienyl, benzothienyl or indolyl, each optionally substituted by 1 or 2 substituents each independently selected from C1 -C4 alkyl, C1 -C4 alkoxy, halo and trifluormethyl; R2 is --CO2 H, --CONR3 R4, --CONR5 (C3 -C7 cycloalkyl), --NR5 (C2 -C5 alkanoyl), --NR3 R4, --NR5 CONR5 R6, (C3 -C7 cycloalkyl-C1 -C4 alkyl)R5 N--, --NR5 COCF3, --NR5 SO2 CF3, --NR5 (SO2 C1 -C4 alkyl), --NR5 SO2 NR5 R6, --NR5 (SO2 aryl), --N(aryl) (SO2 C1 -C4 alkyl), --OR5, --O(C3 -C7 cycloalkyl), --SO2 NR5 R6, het3 or a group of formulas: (a), (b), (c), (d), (e), (f), (g) or (h); X is C1 -C4 alkylene; X1 is a direct link or C1 -C6 alkylene; X2 is a direct link, CO, SO2, or NR5 CO; and m is 0, 1 or 2; together with intermediates used in the preparation of compositions containing and the use as tachykinin angatonists of such derivatives. STR1